A Randomized Dose-Ranging Study of Neuropeptide y in Patients with Posttraumatic Stress Disorder

Sehrish Sayed, Nicholas T. Van Dam, Sarah R. Horn, Marin M. Kautz, Michael K. Parides, Sara Costi, Katherine A. Collins, Brian Iacoviello, Dan V. Iosifescu, Aleksander A. Mathé, Steven M. Southwick, Adriana Feder, Dennis S. Charney, James W. Murrough

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Background: Anxiety and trauma-related disorders are among the most prevalent and disabling medical conditions in the United States, and posttraumatic stress disorder in particular exacts a tremendous public health toll. We examined the tolerability and anxiolytic efficacy of neuropeptide Y administered via an intranasal route in patients with posttraumatic stress disorder. Methods: Twenty-six individuals were randomized in a cross-over, single ascending dose study into 1 of 5 cohorts: 1.4 mg (n = 3), 2.8 mg (n = 6), 4.6 mg (n = 5), 6.8 mg (n = 6), and 9.6 mg (n = 6). Each individual was dosed with neuropeptide Y or placebo on separate treatment days 1 week apart in random order under double-blind conditions. Assessments were conducted at baseline and following a trauma script symptom provocation procedure subsequent to dosing. Occurrence of adverse events represented the primary tolerability outcome. The difference between treatment conditions on anxiety as measured by the Beck Anxiety Inventory and the State-Trait Anxiety Inventory immediately following the trauma script represented efficacy outcomes. Results: Twenty-four individuals completed both treatment days. Neuropeptide Y was well tolerated up to and including the highest dose. There was a significant interaction between treatment and dose; higher doses of neuropeptide Y were associated with a greater treatment effect, favoring neuropeptide Y over placebo on Beck Anxiety Inventory score (F1,20=4.95, P = .038). There was no significant interaction for State-Trait Anxiety Inventory score.Conclusions: Our study suggests that a single dose of neuropeptide Y is well tolerated up to 9.6 mg and may be associated with anxiolytic effects. Future studies exploring the safety and efficacy of neuropeptide Y in stress-related disorders are warranted. The reported study is registered at: http://clinicaltrials.gov (ID: NCT01533519).

Original languageEnglish (US)
Pages (from-to)3-11
Number of pages9
JournalInternational Journal of Neuropsychopharmacology
Volume21
Issue number1
DOIs
StatePublished - Jan 1 2018
Externally publishedYes

Fingerprint

Neuropeptide Y
Post-Traumatic Stress Disorders
Neuropeptides
Anxiety
Equipment and Supplies
Anti-Anxiety Agents
Wounds and Injuries
Placebos
Therapeutics
Public Health
Safety

Keywords

  • anxiety
  • neuropeptide Y
  • posttraumatic stress disorder
  • resilience
  • stress
  • trauma

ASJC Scopus subject areas

  • Pharmacology
  • Psychiatry and Mental health
  • Pharmacology (medical)

Cite this

A Randomized Dose-Ranging Study of Neuropeptide y in Patients with Posttraumatic Stress Disorder. / Sayed, Sehrish; Van Dam, Nicholas T.; Horn, Sarah R.; Kautz, Marin M.; Parides, Michael K.; Costi, Sara; Collins, Katherine A.; Iacoviello, Brian; Iosifescu, Dan V.; Mathé, Aleksander A.; Southwick, Steven M.; Feder, Adriana; Charney, Dennis S.; Murrough, James W.

In: International Journal of Neuropsychopharmacology, Vol. 21, No. 1, 01.01.2018, p. 3-11.

Research output: Contribution to journalArticle

Sayed, S, Van Dam, NT, Horn, SR, Kautz, MM, Parides, MK, Costi, S, Collins, KA, Iacoviello, B, Iosifescu, DV, Mathé, AA, Southwick, SM, Feder, A, Charney, DS & Murrough, JW 2018, 'A Randomized Dose-Ranging Study of Neuropeptide y in Patients with Posttraumatic Stress Disorder', International Journal of Neuropsychopharmacology, vol. 21, no. 1, pp. 3-11. https://doi.org/10.1093/ijnp/pyx109
Sayed, Sehrish ; Van Dam, Nicholas T. ; Horn, Sarah R. ; Kautz, Marin M. ; Parides, Michael K. ; Costi, Sara ; Collins, Katherine A. ; Iacoviello, Brian ; Iosifescu, Dan V. ; Mathé, Aleksander A. ; Southwick, Steven M. ; Feder, Adriana ; Charney, Dennis S. ; Murrough, James W. / A Randomized Dose-Ranging Study of Neuropeptide y in Patients with Posttraumatic Stress Disorder. In: International Journal of Neuropsychopharmacology. 2018 ; Vol. 21, No. 1. pp. 3-11.
@article{8d12bf576d174fe29c0416cc59c9756c,
title = "A Randomized Dose-Ranging Study of Neuropeptide y in Patients with Posttraumatic Stress Disorder",
abstract = "Background: Anxiety and trauma-related disorders are among the most prevalent and disabling medical conditions in the United States, and posttraumatic stress disorder in particular exacts a tremendous public health toll. We examined the tolerability and anxiolytic efficacy of neuropeptide Y administered via an intranasal route in patients with posttraumatic stress disorder. Methods: Twenty-six individuals were randomized in a cross-over, single ascending dose study into 1 of 5 cohorts: 1.4 mg (n = 3), 2.8 mg (n = 6), 4.6 mg (n = 5), 6.8 mg (n = 6), and 9.6 mg (n = 6). Each individual was dosed with neuropeptide Y or placebo on separate treatment days 1 week apart in random order under double-blind conditions. Assessments were conducted at baseline and following a trauma script symptom provocation procedure subsequent to dosing. Occurrence of adverse events represented the primary tolerability outcome. The difference between treatment conditions on anxiety as measured by the Beck Anxiety Inventory and the State-Trait Anxiety Inventory immediately following the trauma script represented efficacy outcomes. Results: Twenty-four individuals completed both treatment days. Neuropeptide Y was well tolerated up to and including the highest dose. There was a significant interaction between treatment and dose; higher doses of neuropeptide Y were associated with a greater treatment effect, favoring neuropeptide Y over placebo on Beck Anxiety Inventory score (F1,20=4.95, P = .038). There was no significant interaction for State-Trait Anxiety Inventory score.Conclusions: Our study suggests that a single dose of neuropeptide Y is well tolerated up to 9.6 mg and may be associated with anxiolytic effects. Future studies exploring the safety and efficacy of neuropeptide Y in stress-related disorders are warranted. The reported study is registered at: http://clinicaltrials.gov (ID: NCT01533519).",
keywords = "anxiety, neuropeptide Y, posttraumatic stress disorder, resilience, stress, trauma",
author = "Sehrish Sayed and {Van Dam}, {Nicholas T.} and Horn, {Sarah R.} and Kautz, {Marin M.} and Parides, {Michael K.} and Sara Costi and Collins, {Katherine A.} and Brian Iacoviello and Iosifescu, {Dan V.} and Math{\'e}, {Aleksander A.} and Southwick, {Steven M.} and Adriana Feder and Charney, {Dennis S.} and Murrough, {James W.}",
year = "2018",
month = "1",
day = "1",
doi = "10.1093/ijnp/pyx109",
language = "English (US)",
volume = "21",
pages = "3--11",
journal = "International Journal of Neuropsychopharmacology",
issn = "1461-1457",
publisher = "Cambridge University Press",
number = "1",

}

TY - JOUR

T1 - A Randomized Dose-Ranging Study of Neuropeptide y in Patients with Posttraumatic Stress Disorder

AU - Sayed, Sehrish

AU - Van Dam, Nicholas T.

AU - Horn, Sarah R.

AU - Kautz, Marin M.

AU - Parides, Michael K.

AU - Costi, Sara

AU - Collins, Katherine A.

AU - Iacoviello, Brian

AU - Iosifescu, Dan V.

AU - Mathé, Aleksander A.

AU - Southwick, Steven M.

AU - Feder, Adriana

AU - Charney, Dennis S.

AU - Murrough, James W.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Background: Anxiety and trauma-related disorders are among the most prevalent and disabling medical conditions in the United States, and posttraumatic stress disorder in particular exacts a tremendous public health toll. We examined the tolerability and anxiolytic efficacy of neuropeptide Y administered via an intranasal route in patients with posttraumatic stress disorder. Methods: Twenty-six individuals were randomized in a cross-over, single ascending dose study into 1 of 5 cohorts: 1.4 mg (n = 3), 2.8 mg (n = 6), 4.6 mg (n = 5), 6.8 mg (n = 6), and 9.6 mg (n = 6). Each individual was dosed with neuropeptide Y or placebo on separate treatment days 1 week apart in random order under double-blind conditions. Assessments were conducted at baseline and following a trauma script symptom provocation procedure subsequent to dosing. Occurrence of adverse events represented the primary tolerability outcome. The difference between treatment conditions on anxiety as measured by the Beck Anxiety Inventory and the State-Trait Anxiety Inventory immediately following the trauma script represented efficacy outcomes. Results: Twenty-four individuals completed both treatment days. Neuropeptide Y was well tolerated up to and including the highest dose. There was a significant interaction between treatment and dose; higher doses of neuropeptide Y were associated with a greater treatment effect, favoring neuropeptide Y over placebo on Beck Anxiety Inventory score (F1,20=4.95, P = .038). There was no significant interaction for State-Trait Anxiety Inventory score.Conclusions: Our study suggests that a single dose of neuropeptide Y is well tolerated up to 9.6 mg and may be associated with anxiolytic effects. Future studies exploring the safety and efficacy of neuropeptide Y in stress-related disorders are warranted. The reported study is registered at: http://clinicaltrials.gov (ID: NCT01533519).

AB - Background: Anxiety and trauma-related disorders are among the most prevalent and disabling medical conditions in the United States, and posttraumatic stress disorder in particular exacts a tremendous public health toll. We examined the tolerability and anxiolytic efficacy of neuropeptide Y administered via an intranasal route in patients with posttraumatic stress disorder. Methods: Twenty-six individuals were randomized in a cross-over, single ascending dose study into 1 of 5 cohorts: 1.4 mg (n = 3), 2.8 mg (n = 6), 4.6 mg (n = 5), 6.8 mg (n = 6), and 9.6 mg (n = 6). Each individual was dosed with neuropeptide Y or placebo on separate treatment days 1 week apart in random order under double-blind conditions. Assessments were conducted at baseline and following a trauma script symptom provocation procedure subsequent to dosing. Occurrence of adverse events represented the primary tolerability outcome. The difference between treatment conditions on anxiety as measured by the Beck Anxiety Inventory and the State-Trait Anxiety Inventory immediately following the trauma script represented efficacy outcomes. Results: Twenty-four individuals completed both treatment days. Neuropeptide Y was well tolerated up to and including the highest dose. There was a significant interaction between treatment and dose; higher doses of neuropeptide Y were associated with a greater treatment effect, favoring neuropeptide Y over placebo on Beck Anxiety Inventory score (F1,20=4.95, P = .038). There was no significant interaction for State-Trait Anxiety Inventory score.Conclusions: Our study suggests that a single dose of neuropeptide Y is well tolerated up to 9.6 mg and may be associated with anxiolytic effects. Future studies exploring the safety and efficacy of neuropeptide Y in stress-related disorders are warranted. The reported study is registered at: http://clinicaltrials.gov (ID: NCT01533519).

KW - anxiety

KW - neuropeptide Y

KW - posttraumatic stress disorder

KW - resilience

KW - stress

KW - trauma

UR - http://www.scopus.com/inward/record.url?scp=85041207894&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041207894&partnerID=8YFLogxK

U2 - 10.1093/ijnp/pyx109

DO - 10.1093/ijnp/pyx109

M3 - Article

C2 - 29186416

AN - SCOPUS:85041207894

VL - 21

SP - 3

EP - 11

JO - International Journal of Neuropsychopharmacology

JF - International Journal of Neuropsychopharmacology

SN - 1461-1457

IS - 1

ER -